FI116385B - (R)-(-)-2-[5-(4-fluorifenyyli)-3-pyridyyli-metyyliaminometyyli]kromaani keskushermoston sairauksien hoitoa varten - Google Patents

(R)-(-)-2-[5-(4-fluorifenyyli)-3-pyridyyli-metyyliaminometyyli]kromaani keskushermoston sairauksien hoitoa varten Download PDF

Info

Publication number
FI116385B
FI116385B FI954874A FI954874A FI116385B FI 116385 B FI116385 B FI 116385B FI 954874 A FI954874 A FI 954874A FI 954874 A FI954874 A FI 954874A FI 116385 B FI116385 B FI 116385B
Authority
FI
Finland
Prior art keywords
fluorophenyl
pyridylmethylaminomethyl
chroman
acid
salt
Prior art date
Application number
FI954874A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI954874A0 (fi
FI954874L (fi
Inventor
Henning Boettcher
Gerd Bartoszyk
Hartmut Greiner
Jean-Jacques Berthelon
Michel Brunet
Ralf Devant
Marc Noblet
Jean-Jacques Zeiller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of FI954874A0 publication Critical patent/FI954874A0/fi
Publication of FI954874L publication Critical patent/FI954874L/fi
Application granted granted Critical
Publication of FI116385B publication Critical patent/FI116385B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/16Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring not being further substituted
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/64Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
FI954874A 1994-10-14 1995-10-13 (R)-(-)-2-[5-(4-fluorifenyyli)-3-pyridyyli-metyyliaminometyyli]kromaani keskushermoston sairauksien hoitoa varten FI116385B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94116223 1994-10-14
EP94116223 1994-10-14

Publications (3)

Publication Number Publication Date
FI954874A0 FI954874A0 (fi) 1995-10-13
FI954874L FI954874L (fi) 1996-04-15
FI116385B true FI116385B (fi) 2005-11-15

Family

ID=8216383

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954874A FI116385B (fi) 1994-10-14 1995-10-13 (R)-(-)-2-[5-(4-fluorifenyyli)-3-pyridyyli-metyyliaminometyyli]kromaani keskushermoston sairauksien hoitoa varten

Country Status (27)

Country Link
US (1) US5767132A (da)
EP (2) EP0707007B1 (da)
JP (1) JP3880645B2 (da)
KR (1) KR100389497B1 (da)
CN (1) CN1246319C (da)
AT (1) ATE210657T1 (da)
AU (1) AU703637B2 (da)
BR (1) BR9504379A (da)
CA (1) CA2160447C (da)
CO (1) CO4480021A1 (da)
CZ (1) CZ292104B6 (da)
DE (1) DE69524528T2 (da)
DK (1) DK0707007T3 (da)
ES (1) ES2169102T3 (da)
FI (1) FI116385B (da)
HU (1) HU227883B1 (da)
MX (1) MX9504332A (da)
NO (1) NO308848B1 (da)
PL (1) PL181165B1 (da)
PT (1) PT707007E (da)
RU (1) RU2155753C2 (da)
SI (1) SI0707007T1 (da)
SK (1) SK283870B6 (da)
TR (1) TR199501253A2 (da)
TW (1) TW420664B (da)
UA (1) UA45952C2 (da)
ZA (1) ZA958673B (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004523A1 (es) * 1995-11-06 1998-12-16 American Home Prod 2-(AMINOMETIL)-3,4,7,9-TETRAHIDRO-2H-PIRANO-[2,3e] INDOL-8-ONAS Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
JP2000516210A (ja) 1996-07-12 2000-12-05 ロイコサイト,インコーポレーテッド ケモカインレセプターアンタゴニストとその使用方法
FR2756284B1 (fr) * 1996-11-26 2000-04-28 Adir Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR9807703A (pt) * 1997-02-18 2000-05-02 American Home Prod Derivados de 4-aminoalcóxi-1,3-diidrobenzoimidazol-2-ona, suas preparações e seus usos como agonistas (d2) auto-receptores da dopamina
KR20000071124A (ko) * 1997-02-18 2000-11-25 이곤 이 버그 4-아미노알콕시-1,3-디하이드로벤조이미다졸-2-티온 유도체,이의 제조방법 및 도파민 자가수용체(d2) 효능제로서의 이의용도
US5922715A (en) * 1997-02-18 1999-07-13 American Home Products Corporation 5-aminoalkoxy-1, 4-dihydroquinoxaline-2, 3-diones
US6127380A (en) * 1997-02-18 2000-10-03 American Home Products Corporation 4-aminoalkoxy-1H-benzoimidazoles
US5990144A (en) * 1997-02-18 1999-11-23 American Home Products Corporation 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one dopamine autoreceptor agonists
US5972958A (en) * 1997-02-18 1999-10-26 American Home Products Corporation 4-aminoalkoxy-1,3-dihydro-benzoimidazol-2-thiones
CA2278757A1 (en) * 1997-02-18 1998-08-20 Uresh Shantilal Shah 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists
JP2001509814A (ja) * 1997-02-18 2001-07-24 アメリカン・ホーム・プロダクツ・コーポレイション 4−アミノアルコキシ−1h−ベンゾイミダゾール誘導体、それらの調製およびそれらのドパミン自己受容体(d▲下2▼)作動薬としての使用
CO5011067A1 (es) * 1997-11-03 2001-02-28 Novartis Ag Derivados de bifenilo como productos farmaceuticos, su pre- paracion y composiciones farmaceuticas que los contienen
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
FR2786767B1 (fr) * 1998-12-02 2001-02-23 Pf Medicament Nouveaux derives de 3-alkoxybenzylamines et leur utilisation a titre de medicaments pour le traitement de la schizophrenie
DE19858341A1 (de) * 1998-12-17 2000-06-21 Merck Patent Gmbh Chromanderivate
WO2000056707A1 (en) * 1999-03-24 2000-09-28 Sepracor, Inc. Diaryl thioethers, compositions and uses thereof
DE10005150A1 (de) * 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004151D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
DE10029371A1 (de) * 2000-06-20 2002-01-03 Merck Patent Gmbh Heterocyclische Aminoalkylpyridinderivate als Psychopharmaka
DE10044091A1 (de) * 2000-09-07 2002-04-04 Merck Patent Gmbh Chromanonderivate
HUP0302761A2 (hu) * 2000-11-14 2003-12-29 Merck Patent Gmbh. Kombinált szelektív dopamin D2 receptor antagonista és 5-HT1A receptor agonista hatású vegyületek alkalmazása gyógyszerkészítmények előállítására
DE10120619A1 (de) 2001-04-26 2002-10-31 Merck Patent Gmbh 2-(5-(4-Fluorphenyl)-3-pyridylmethylaminomethyl-chroman
AU2002355170B2 (en) 2001-07-26 2007-06-07 Merck Patent Gmbh Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0102639D0 (sv) 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0102641D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
EP1427724B1 (en) * 2001-09-19 2006-05-03 MERCK PATENT GmbH Novel use of substituted aminomethyl chromans
WO2003029239A1 (en) 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
JPWO2003040382A1 (ja) * 2001-11-09 2005-03-03 株式会社カネカ 光学活性クロマン誘導体の製造法および中間体
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en) 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
KR100783255B1 (ko) 2004-02-13 2007-12-06 워너-램버트 캄파니 엘엘씨 안드로젠 수용체 조절제
JP2007532621A (ja) 2004-04-13 2007-11-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンモジュレータ
WO2005102990A1 (en) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Androgen modulators
EP1781598A1 (en) 2004-07-08 2007-05-09 Warner-Lambert Company LLC Androgen modulators
AR055054A1 (es) * 2005-04-22 2007-08-01 Wyeth Corp Cristales formados de clorhidrato de (((2r)-7-(2,6-diclorofenil)-5-fluoro-2,3- dihidro-1-benzofurano-2-il) metil ) amina
CN101203505A (zh) * 2005-04-22 2008-06-18 惠氏公司 苯并二氢吡喃和苯并吡喃衍生物及其用途
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
TW200811182A (en) 2006-05-25 2008-03-01 Wyeth Corp Oxindoledioxans, synthesis thereof, and intermediates thereto
EP2699543B1 (en) 2011-04-19 2016-03-02 Integrative Research Laboratories Sweden AB Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission
US10577308B2 (en) * 2015-03-26 2020-03-03 The Florey Institute Sodium channel modulators
FI3976581T3 (fi) 2019-05-24 2024-01-31 Irl 790 Ab [2-(3-fluori-5-metaani-sulfonyylifenoksi)etyyli](propyli)amiinin viinihapposuolat

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2364685C3 (de) * 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
FR2397417A1 (fr) * 1977-07-12 1979-02-09 Parcor Procede de preparation de derives de la thienopyridine
JPS55124742A (en) * 1979-03-20 1980-09-26 Kyowa Hakko Kogyo Co Ltd Novel aminoalcohol derivative
SU1074094A1 (ru) * 1982-07-30 1992-04-23 Научно-исследовательский институт фармакологии АМН СССР Гидрохлорид 4-бензилпиперазида 3-метилбензофуран-2-карбоновой кислоты, обладающий психотропной активностью
CA1337429C (en) * 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
SI9300097B (en) * 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
JPH05255302A (ja) * 1992-03-09 1993-10-05 Yamanouchi Pharmaceut Co Ltd 新規なクロマニルオキシアルキルアミン誘導体
DE4226527A1 (de) * 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
WO1995005383A1 (en) * 1993-08-19 1995-02-23 Janssen Pharmaceutica N.V. Vasocontrictive dihydrobenzopyran derivatives

Also Published As

Publication number Publication date
EP0707007A1 (en) 1996-04-17
DK0707007T3 (da) 2002-03-18
JP3880645B2 (ja) 2007-02-14
JPH08225501A (ja) 1996-09-03
FI954874A0 (fi) 1995-10-13
HU227883B1 (en) 2012-05-29
CO4480021A1 (es) 1997-07-09
ES2169102T3 (es) 2002-07-01
HU9502976D0 (en) 1995-12-28
FI954874L (fi) 1996-04-15
EP0707007B1 (en) 2001-12-12
MX9504332A (es) 1997-03-29
PT707007E (pt) 2002-06-28
NO954080L (no) 1996-04-15
US5767132A (en) 1998-06-16
HUT75644A (en) 1997-05-28
RU2155753C2 (ru) 2000-09-10
TW420664B (en) 2001-02-01
SI0707007T1 (en) 2002-04-30
EP1123933A1 (en) 2001-08-16
TR199501253A2 (tr) 1996-06-21
PL181165B1 (pl) 2001-06-29
SK126695A3 (en) 1996-06-05
CZ292104B6 (cs) 2003-07-16
CN1130180A (zh) 1996-09-04
PL310932A1 (en) 1996-04-15
NO308848B1 (no) 2000-11-06
DE69524528T2 (de) 2002-08-01
KR960014123A (ko) 1996-05-22
AU3421895A (en) 1996-04-26
CA2160447C (en) 2008-09-02
KR100389497B1 (ko) 2003-09-19
ZA958673B (en) 1996-05-22
CZ266195A3 (en) 1996-04-17
CA2160447A1 (en) 1996-04-15
UA45952C2 (uk) 2002-05-15
BR9504379A (pt) 1997-05-27
ATE210657T1 (de) 2001-12-15
AU703637B2 (en) 1999-03-25
NO954080D0 (no) 1995-10-13
CN1246319C (zh) 2006-03-22
SK283870B6 (sk) 2004-03-02
DE69524528D1 (de) 2002-01-24

Similar Documents

Publication Publication Date Title
FI116385B (fi) (R)-(-)-2-[5-(4-fluorifenyyli)-3-pyridyyli-metyyliaminometyyli]kromaani keskushermoston sairauksien hoitoa varten
JP4065034B2 (ja) ピペリジン類およびピペラジン類
US5723614A (en) Benzofurans
JP4740115B2 (ja) 置換ピラゾール
US6310068B1 (en) Benzonitriles and benzofluorides
JP4059671B2 (ja) ベンズイミダゾール誘導体
US20090291963A1 (en) Substituted indoles
HUP9904521A2 (hu) Piperazinszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények
JP4740116B2 (ja) 精神疾患および神経障害の処置のための5−ht受容体アンタゴニスト
JP2011153144A (ja) 置換ピラゾール化合物
JP4833832B2 (ja) ピラゾール化合物
JP2002543079A (ja) うつ病治療用のアザインドール誘導体
AU2004226279B2 (en) Chromenone indoles
JP4198183B2 (ja) 選択的ドーパミンd3アゴニストとしてのアミノピリジン誘導体
KR20030022390A (ko) 5-hta1 수용체 및/또는 도파민 d2 수용체와 관련된질병의 치료를 위한 크로메논 유도체 및 이의 용도
JP4563817B2 (ja) インドール誘導体およびその5−ht配位子としての使用
ES2304599T3 (es) Derivados de bencofurano y su empleo como antidepresivos y ansioliticos.
RU2379307C2 (ru) Соединение циклического амина
US7834032B2 (en) Piperidine derivatives
CN118019738A (zh) 作为sting拮抗剂的小分子脲衍生物

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 116385

Country of ref document: FI

MA Patent expired